🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07408388
Active, not recruiting Observational

Pulse Oximeter Accuracy During Stable Hypoxia Plateaus

NCT07408388 · tracked via the Priya Life Science USA tracker
Sponsor
Nihon Kohden
Phase
Observational
Started
2025-12-03
Last updated
2026-02-17

Condition(s) studied

Hypoxia

Investigational drug(s) / intervention(s)

Pulse OximeterInduced hypoxia through breathing nitrogen-air-carbon dioxide mixture

Pulse Oximeter: OLV-4202 pulse oximeter ((SW version: 01-17)

Induced hypoxia through breathing nitrogen-air-carbon dioxide mixture: Subjects will be placed in a seated semi-reclined position. Subjects will breathe a nitrogen-air-carbon dioxide mixture to produce the desired level of hypoxemia. Stable, safe and controlled hypoxia is obtained by breath-by-breath analysis of respiratory gas using a gas analyzer that permits the inspired gas mixture to be adjusted to achieve the desired degree of blood oxygen saturation. Study is observational to see response of pulse oximeter. Intervention (above) is not therapeutic, rather is simply used to vary oxygen levels in subjects.

Study summary

The aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling. Study will be used with healthy volunteers at rest.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The subject is male or female, aged 18 to 50. * The subject is in good general health with no evidence of any medical problems * The subject is fluent in both written and spoken English. * The subject has provided informed consent and is willing to comply with the study procedures. Exclusion Criteria: 1. The subject has a BMI above 40 2. The subject has blood pressure above 160 systolic or 95 diastolic 3. The subject has a known history of heart disease, lung disease, kidney or liver disease. 4. Diagnosis of asthma, sleep apnea, or use of CPAP. 5. Subject has diabetes. 6. Subject has a clotting disorder. 7. The subject has a hemoglobinopathy or history of anemia, per subject report or the first blood sample, that in the opinion of the investigator, would make them unsuitable for study participation. (COHb\<3%, MetHb\<2%, ctHb\>10 g/dL). 8. The subject has any other serious systemic illness. 9. The subject has smoked in the last 12 hours. 10. Any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators would interfere with the sensors working correctly. 11. The subject has a history of fainting or vasovagal response. 12. The subject has a history of sensitivity to local anesthesia. 13. The subject has a diagnosis of Raynaud's disease. 14. The subject has unacceptable collateral circulation based on exam by the investigator (Allen's test). 15. The subject is pregnant, lactating or trying to get pregnant. 16. Subjects who have uneven skin tones at the forehead or the sensor site. 17. The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with study procedures. 18. The subject has any other condition, which in the opinion of the investigators would make them unsuitable for the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Vital Sign Research Group San Francisco California

More Nihon Kohden trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07408388 on ClinicalTrials.gov ↗ ← All trials in the USA